NEW YORK (GenomeWeb News) – SomaLogic, New England Biolabs, and Gilead Sciences are suing Enzymatics in federal court for patent infringement.

In a lawsuit filed on Wednesday in US District Court for the District of Massachusetts, the plaintiffs accuse Enzymatics of infringing US Patent Nos. 5,670,637, titled "Nucleic acid ligands" and 5,874,557, titled "Nucleic acid ligand inhibitors to DNA polymerase."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.